SciCombinator

Discover the most talked about and latest scientific content & concepts.

Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.

OPEN Blood cells, molecules & diseases | 20 Nov 2012

I Bendikov-Bar, G Maor, M Filocamo and M Horowitz
Abstract
Gaucher disease (GD) is characterized by accumulation of glucosylceramide in lysosomes due to mutations in the GBA1 gene encoding the lysosomal hydrolase β-glucocerebrosidase (GCase). The disease has a broad spectrum of phenotypes, which were divided into three different Types; Type 1 GD is not associated with primary neurological disease while Types 2 and 3 are associated with central nervous system disease. GCase molecules are synthesized on endoplasmic reticulum (ER)-bound polyribosomes, translocated into the ER and following modifications and correct folding, shuttle to the lysosomes. Mutant GCase molecules, which fail to fold correctly, undergo ER associated degradation (ERAD) in the proteasomes, the degree of which is one of the factors that determine GD severity. Several pharmacological chaperones have already been shown to assist correct folding of mutant GCase molecules in the ER, thus facilitating their trafficking to the lysosomes. Ambroxol, a known expectorant, is one such chaperone. Here we show that ambroxol increases both the lysosomal fraction and the enzymatic activity of several mutant GCase variants in skin fibroblasts derived from Type 1 and Type 2 GD patients.
Tweets*
2
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
1
SC clicks
3
Concepts
Brain, Gaucher's disease, Cell, Neurology, Nervous system, Central nervous system, Glucocerebrosidase, Endoplasmic reticulum
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com